breast cancer - adjuvant | breast cancer - HER2-positive | breast cancer - triple negative | ||||||
breast cancer - adjuvant | es-BC - HER2 negative - (neo)adjuvant (NA) | es-BC - TNBC - NA - all population | es-BC - TNBC - NA - PDL1 positive | mBC - TNBC - L1 - all population | mBC - TNBC - L1 - PDL1 positive | mBC - TNBC - L2 - all population | mBC - TNBC - L2 - PDL1 positive | |
anti-PD-(L)1 | ||||||||
atezolizumab based treatment | ||||||||
atezolizumab plus carboplatin plus nab-paclitaxel | ||||||||
atezolizumab plus nab-paclitaxel | IMpassion-130 ... | IMpassion-130 ... | ||||||
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide | IMpassion-031 ... | IMpassion-031 ... | ||||||
atezolizumab plus paclitaxel | ||||||||
durvalumab based treatment | ||||||||
durvalumab alone | GeparNuevo | |||||||
pembrolizumab based treatment | ||||||||
pembrolizumab alone | KEYNOTE-522 | KEYNOTE-522 | KEYNOTE-119 ... | KEYNOTE-119 ... KEYNOTE-119 ... | ||||
pembrolizumab plus paclitxel followed by doxorubicin plus cyclophosphamide | ||||||||
pembrolizumab plus SoC | KEYNOTE-355 ... | KEYNOTE-355 ... KEYNOTE-355 ... |